In our study, HER2 heterogeneous expression between primary breast tumors and liver metastases reached 38%, suggesting that the inclusion of HER2 low expression in the analysis significantly increases the observed rate of HER2 heterogeneity. Here, ERBB2 is linked to breast neoplasm.